Docteur DIVI CORNEC

• Caractérisation des lymphocytes B auto-réactifs dans le syndrome de Sjögren

  2021

  Doctorant·e : Nedra Chriti

  Immunologie🎓 Brest

• PreSSto - Pre-Sjögren Syndrome Targeted Immunology Evaluation

  Doctorant·e : Rudolf Corty

  Immunologie🎓 Université de Brest (2025-….)

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Bibliographie

• The immune cell landscape analyzed by imaging mass cytometry in the muscle of patients with inclusion body myositis associated or not with Sjögren’s disease

  2026

  ArticleRheumatology

• Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review

  2026

  ArticleJoint Bone Spine

• Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica

  2026

  ArticleJoint Bone Spine

• Optimal Formalin-Fixed Paraffin Embedded Sample Preservation for Efficient Staining in Multiplex Imaging

  2026

  ArticleLaboratory Investigation

• Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease

  2025

  ArticleAnnals of the Rheumatic Diseases

• [Fourteen ways to make B cells the most interesting target in systemic lupus erythematosus].

  2025

  ArticleLa Revue de Médecine Interne

• A Systematic Review of Clinical Trial Designs and Outcome Measures in Sjögren Disease Randomized Controlled Trials

  2025

  ArticleJournal of Rheumatology

• Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica

  2025

  ArticleArthritis & rheumatology

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CHRU BREST SITE HOPITAL CAVALE BLANCHE

  Boulevard TANGUY PRIGENT, 29609 Brest

  ☎ 0298223333Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (3)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Un espoir de traitement contre les vascularites à Anca, maladies qui détruisent les organes - Le Point

  📰 Le Point · 17/12/2024

  <a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPbkRNVDI2eVBoQTQ5T0VjeEpkTm80WG5RSFJYZ3cyaHNYU1NqOURTWTBVaFpyZW5wUGlkZEVhMnJVNkdVTWtJSTVoeGhLS2Y0RDhUeW1ERmQ2dndmazk3Nk9aemdHd2w5NkZtT2wwM2YyZjFHdW5XWExzTVdzZ1dvLWZDejBCX01TQlFlSEtvVTRjQmhMTW9zLWxTTDlmc0QyQ01PdlAwYmdEZlllTDhSVkFqa3lXTzh6Rm

• Nécrologie. À Brest, Pierre Youinou, brillant chercheur, est décédé - Ouest-France

  📰 Ouest-France · 29/08/2022

  <a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQTklEV3JKOXljSXZtVElCOUs2YVltMHpkUDNTdFFoejZMeGw1bzV4TnpJWDU5Z044MVhxRy1odkU0YmpJeDNiZ2g5aUNRTmZkS0hLYndNUktWa0c3V01VcS02SHdzYmlBZ05SdWRJM2J4OGl4d3R1blpqYVhVdnZNWDlaQlBVa2QwaWxaMDBUaXNRSkVoZ19wUE9kclVVNC02cENoc25EbG9IWkYzcXBBbHVLem50b090ZG

• Awena. Conférence sur un syndrome méconnu - Le Télégramme

  📰 Le Télégramme · 18/02/2018

  <a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOMHNaTnl3SWM2QjQwNmZWRTJZaGkzVVB1U2kwVVR4Q3BFLVBwU29ZVk5rcGlxZzhmQWtjXzNzSlZiMlZHOVVZSnZXQ2huZG1HRlBkQjFIZ0JWcVh1RHJWU2JZUjlHbUk3OXRUSFgyZEt3blNXMDNFYVdmamdWc01uRFE4RVBXbU82blluOGs3d2lyVTUwQ3VvVWNQT2pCbnhJM2NxOWx6Zm5TNmp3czhqZ1p1UQ?oc=5" t

Top publications · les plus citées

• 1

  Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice

  Rheumatology (Oxford, England) · 2023

  📚 48 citations🎯 RCR 7.21Top 4% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract ANCA-associated vasculitides (AAV) are a group of rare, primary, systemic necrotizing small-vessel vasculitides. Granulomatosis with polyangiitis and microscopic polyangiitis account for ∼80–90% of all AAV. Exposure to silica dust, farming and chronic nasal Staphylococcus aureus carriage are associated with increased risk of developing AAV. When a diagnosis of AAV is suspected, as in patients with multisystem organ dysfunction or those with features such as chronic recurrent rhinosinusitis, cavitated lung nodules, palpable purpura or acute kidney injury, then appropriate further investigations are needed, including ANCA testing. In this scenario, a structured clinical assessment should be conducted, evaluating all the organs possibly involved, and tissue biopsy may be necessary for confirmation of the diagnosis. Therapeutic algorithms vary based on the severity of AAV, the clinical diagnosis/ANCA specificity, and the patient’s age, weight, comorbidities and prognosis. Recent data favour rituximab as a preferable option for both induction and maintenance of remission. In addition, regimens with less glucocorticoids are equally effective and safer in inducing remission compared with conventional regimens, and avacopan is an effective glucocorticoid-sparing option. In contrast, there is not compelling evidence to support the routine use of plasma exchange in addition to standard remission-induction therapy in AAV. ANCA and other biomarkers can be helpful in association with clinical assessment to guide diagnosis and treatment decisions. Patients should be frequently evaluated during follow-up for possible disease relapses or treatment-related morbidity, and for monitoring damage accrual, especially metabolic and cardiovascular damage.

• 2

  CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

  The Lancet. Rheumatology · 2025

  📚 28 citations🎯 RCR 10.18
• 3

  Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation

  Arthritis & rheumatology (Hoboken, N.J.) · 2024

  📚 24 citations🎯 RCR 4.97Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectiveThe biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti‐Ro60/SSA antibodies, whereas the significance of anti‐Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti‐Ro52/TRIM21 antibody status.MethodsPatients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52−/Ro60−), isolated anti‐Ro52/TRIM21 positive (Ro52+), isolated anti‐Ro60/SSA positive (Ro60+), and double‐positive (Ro52+/Ro60+) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients.ResultsIn the DIApSS cohort, Ro52+/Ro60+ patients showed significantly more parotidomegaly (33.3% vs 0%–11%) along with higher β2‐microglobulin (P = 0.0002), total immunoglobulin (P &lt; 0.0001), and erythrocyte sedimentation rate levels (P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%–25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis (P = 0.046), inflammation (P = 0.005), hypergammaglobulinemia (P &lt; 0.0001), positive RF (P &lt; 0.0001), leukopenia (P = 0.004), and lymphopenia (P = 0.009) in Ro52+/Ro60+ patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities (P = 0.002). Transcriptome analysis linked anti‐Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations.ConclusionThese results suggest that the combination of anti‐Ro52/TRIM21 and anti‐Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti‐Ro52/TRIM21 antibodies.image

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Complex relationships between inflammatory manifestations/type 1 and type 2 symptoms in systemic lupus erythematosus: A narrative literature review

  Collection2023SAGE Journals

  ObjectiveRecent studies have highlighted that systemic lupus erythematosus (SLE) is characterized by different types of symptoms: type 1 symptoms related to inflammation and disease activity and type 2 symptoms such as f

• Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study

  Collection2022figshare

  Abstract Background Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes,

• Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study

  Collection2022figshare

  Abstract Background Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes,

• Complex relationships between inflammatory manifestations/type 1 and type 2 symptoms in systemic lupus erythematosus: A narrative literature review

  Collection2023SAGE Journals

  ObjectiveRecent studies have highlighted that systemic lupus erythematosus (SLE) is characterized by different types of symptoms: type 1 symptoms related to inflammation and disease activity and type 2 symptoms such as f

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche